dulaglutide vs tirzepatide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM Beyond glycemia: Comparing tirzepatide to

Existing observational studies comparing weight reduction with these two treatments were conducted in patients with and without type 2 diabetes before FDA approval of tirzepatide for obesity management [8,9,10,11,12,13,14,15]

Women should consult their healthcare provider about appropriate timing for discontinuation, as the medication has a half-life of approximately 5 days with elimination occurring over several weeks

10-15 gotas de Aceites Esenciales - si lo desea (recomendamos romero, lavanda, menta y manzanilla)

Both methotrexate and GLP-1 receptor agonists should not be used during pregnancy or breastfeeding

The good thing is that telogen effluvium is temporary

Most continue normal routines and soon experience more consistent energy, improved mood, and a stronger metabolism